HC Wainwright Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $60.00

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price objective decreased by HC Wainwright from $80.00 to $60.00 in a report published on Monday morning,Benzinga reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Ultragenyx Pharmaceutical’s Q4 2025 earnings at ($0.71) EPS, FY2025 earnings at ($5.26) EPS, Q1 2026 earnings at ($1.63) EPS, Q2 2026 earnings at ($1.40) EPS, Q3 2026 earnings at ($1.30) EPS, Q4 2026 earnings at ($1.00) EPS and FY2026 earnings at ($5.32) EPS.

Other equities research analysts have also recently issued research reports about the company. Wells Fargo & Company reduced their price objective on Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating for the company in a report on Tuesday, December 30th. Barclays dropped their price target on Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating for the company in a report on Monday, November 24th. Guggenheim decreased their price objective on Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating on the stock in a report on Monday. Jefferies Financial Group lowered their price objective on Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating on the stock in a research report on Tuesday, December 30th. Finally, Robert W. Baird dropped their target price on Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating for the company in a report on Tuesday, December 30th. Sixteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $72.29.

Ultragenyx Pharmaceutical Price Performance

Shares of RARE opened at $24.20 on Monday. The firm has a market capitalization of $2.33 billion, a PE ratio of -4.07 and a beta of 0.15. The company’s 50-day moving average is $32.12 and its 200-day moving average is $31.46. Ultragenyx Pharmaceutical has a fifty-two week low of $18.41 and a fifty-two week high of $46.50.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.58). Ultragenyx Pharmaceutical had a negative return on equity of 414.17% and a negative net margin of 91.95%.The company had revenue of $159.93 million for the quarter, compared to the consensus estimate of $167.42 million. During the same period in the previous year, the firm posted ($1.40) EPS. The business’s quarterly revenue was up 14.6% on a year-over-year basis. Analysts predict that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Howard Horn sold 3,081 shares of the firm’s stock in a transaction on Wednesday, December 10th. The stock was sold at an average price of $36.38, for a total value of $112,086.78. Following the transaction, the chief financial officer owned 95,146 shares in the company, valued at approximately $3,461,411.48. This trade represents a 3.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last quarter, insiders sold 11,108 shares of company stock worth $365,262. Corporate insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Large investors have recently bought and sold shares of the company. Parallel Advisors LLC lifted its stake in shares of Ultragenyx Pharmaceutical by 1,061.9% in the 2nd quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 669 shares during the last quarter. Assetmark Inc. grew its position in Ultragenyx Pharmaceutical by 1,706.7% during the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 1,024 shares during the last quarter. Huntington National Bank increased its holdings in Ultragenyx Pharmaceutical by 56.2% in the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 393 shares in the last quarter. Danske Bank A S acquired a new position in Ultragenyx Pharmaceutical in the 3rd quarter worth about $39,000. Finally, Smartleaf Asset Management LLC raised its position in Ultragenyx Pharmaceutical by 205.4% in the third quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 1,169 shares during the last quarter. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: CEO Emil D. Kakkis will present at the 44th Annual J.P. Morgan Healthcare Conference on Jan. 12, increasing senior-management visibility and providing a live/replay channel for investors to hear program updates and commercialization progress. Ultragenyx CEO to Present at J.P. Morgan Healthcare Conference
• Positive Sentiment: HC Wainwright revised several near-term EPS estimates upward and raised its FY2026 outlook (and maintains a “Buy” rating with a $60 price target), signaling analyst confidence in Ultragenyx’s longer-term revenue profile and helping sentiment. HC Wainwright analyst note (MarketBeat summary)
• Neutral Sentiment: Institutional activity is mixed but notable: large additions from some funds (e.g., FMR materially increased exposure) while others trimmed positions, which can amplify intraday moves but doesn’t single-handedly direct the trend. Quiver / institutional holdings summary
• Negative Sentiment: Guggenheim cut its price target to $52, which can weigh on upside expectations and headline-driven sentiment even if other analysts remain more bullish. Guggenheim Lowers Ultragenyx Price Target to $52
• Negative Sentiment: Reports pointing to a clinical setback have surfaced, raising execution and development risk for pipeline programs; such headlines typically pressure biotech names until details or remediation plans are clear. Ultragenyx Faces Mounting Challenges After Clinical Setback
• Negative Sentiment: An investor alert from Pomerantz LLP signals an active investigation into potential claims by Ultragenyx investors, adding legal/settlement risk and potential headline volatility. Pomerantz Investigates Claims on Behalf of Ultragenyx Investors

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.